18 results about "Heterografts" patented technology

The present disclosure provides a single mouse exhaled breath collection device and proof- of-concept analyses utlizing an ultra- sensitive and customizable EV purification assay, EV- CATCHER® (Extracellular Vesicle Capture by AnTibody of CHoice and Enzymatic Release) assay. Preliminary studies show that this assay work well for the isolation of exhaled extracellular vesicles (exh-EVs) from exhaled breath condensates (EBC) to capture and characterize miRNAs contained in exh-EVs. Because assembling a large enough cohort of asymptomatic subjects requires time, a complementary approach of using humanized animal models has been chosen to comprehensively assess the robustness and sensitivity of transcriptomic (miRNA and mRNA) and proteomic biomarkers contained in tumor exh-EVs and to enable sensitive detection of human primary and secondary lung cancers during their early development. The results of preliminary analyses demonstrate that the purification of exh-EVs with EV-CATCHER® offers specificity and sensitivity, which will be critical for the targeted purification of tumor exh-EVs from the EBC of transgenic, orthotopic, and Patient-Derived Xenograft (PDX) animal models of human lung cancers.

The application provides a reduction-responsive nano delivery system and application thereof in preparation of a drug for treating drug-resistant tumors, and belongs to the pharmaceutical field. The application constructs a reduction-responsive branched copolymer functionalized by pegylation and deoxycholic acid (DA) (referred to as: pegylated branched poly(HPMA-DA)), which can effectively encapsulate small molecule drugs to form a nano delivery system. Experiments prove that the nano delivery system can be taken up by tumor cells, has good tumor targeting, and exhibits excellent anti-tumor effect in tumor xenografts (CDX) derived from non-small cell lung cancer (NSCLC) chemoresistant cell lines and patient-derived xenograft mouse models (PDX). The pegylated branched poly(HPMA-DA) provided by the application has wide application prospect in preparation of a drug carrier, and the nano delivery system provided by the application has wide application prospect in preparation of a drug for treating cancer.

The present application relates to a bifunctional therapeutic substance for treating cancer, comprising a targeting component that targets a tumor-associated antigen and an enzyme that, when delivered to a tumor by the targeting component, converts the tumor phenotype into the phenotype of a mismatched allograft or xenograft. The enzyme is connected to the targeting component. Also disclosed is a method for treating cancer, comprising the step of administering the bifunctional therapeutic substance.

The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same.

The present invention relates to the use of bone graft particles in the preparation of a porous bone graft material comprising an acid-containing self-setting adhesive composition. The bone graft particles have a porous core, the outer surface of which is at least partially covered by an outer layer. The core comprises a core material selected from the group consisting of a heterograft, a bone xenograft, and a bone allograft, or mixtures thereof. And the outer particle layer comprises carbonate.

Disclosed herein include methods and compositions for pig-to-human organ xenotransplantation using genetically modified pigs with triple-gene knockouts and human gene insertions. In some embodiments, the organ xenotransplantation is a pig-to-human kidney xenotransplantation demonstrating the restoration of renal function. Also disclosed are methods and compositions for preventing acute rejection and / or reactivation of porcine herpesvirus, which contributes to advancing xenotransplantation as a viable solution to the global organ shortage.

The present application relates to a bifunctional therapeutic agent for the treatment of cancer, the bifunctional therapeutic agent comprising: a targeting component that targets a tumor-associated antigen; and an enzyme that, when delivered to a tumor by the targeting component, converts a tumor phenotype to a phenotype of an incompatible allograft or xenograft. The enzyme is coupled to the targeting component. Also disclosed is a method for treating cancer comprising administering the bifunctional therapeutic agent.

Provided herein are methods of xenotransplantation, for example, porcine to human transplantation. Also provided herein are extracellular vesicles (“EVs”, e.g., exosomes) and compositions comprising the same. e.g. EVs expressing human CD47. Further provided herein are methods of making EVs and use thereof for xenotransplantation. In some aspects, the methods of xenotransplantation comprise steps of expressing human CD47 on xenografts.

This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine β1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and / or reduced or no endogenous α-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.

The invention provides a preparation method of a biological tissue material, which comprises the following steps: c, carrying out functional modification on a pretreated tissue, namely oxidizing groups on the pretreated tissue and grafting anti-inflammatory and anticoagulant functional groups. The invention also provides the biological tissue material prepared by the preparation method. The service life of the xenograft is prolonged by introducing anticoagulant functional molecules on the basis of non-aldehyde tissue fixation and antigen content reduction, the technical problem that an existing xenograft tissue material is high in antigen content is solved, and the problems of aldehyde group residue, depolymerization and the like caused by glutaraldehyde fixation can be effectively avoided; inflammation, thrombus and easy calcification caused by implantation are effectively improved through functional modification; and the technical problems of immune response of implanted biological tissue materials and the like are also solved.

The present invention relates to compounds of formula (1) or (2), wherein R 1 and R 3 is a purine or a purine analog, and R 2 and R 4 is a small functional group. The present invention also relates to intermediates for the synthesis of compounds of formula 1 or 2. Compounds of formula 1 or 2 are Janus kinase inhibitors and are therefore useful for the treatment of diseases, in particular autoimmune diseases, cancer, Alzheimer's disease or for the prevention of rejection of allografts or xenografts.

Creating a single-cell methylation atlas characterizing an organ of a donor by clustering methylated single-nuclei whole genome sequences (m-snWGS) from a biopsy of the organ based at least in part on differentially methylated patterns of the m-snWGS, assigning a cell type for each cluster based at least in part on correlation of known cell type markers of the organ with the differentially methylated patterns of the m-snWGS; and providing the atlas to include a database with genomic sequences based at least in part on the m-snWGS, methylation patterns of the genomic sequences based at least in part on the m-snWGS, and cell type designation for the genomic sequences based at least in part on the cell type assigned for each cluster.

The present invention relates to compounds of formula 1 or 2,wherein R1 and R3 are purine or a purine analog and R2 and R4 are a small functional group. The invention also relates to intermediates of the synthesis of compounds of formula 1 or 2. Compounds of formula 1 or 2 are Janus kinase inhibitors and thus useful in the treatment of a disease, particularly an autoimmune disease, cancer, Alzheimer's disease or useful in preventing the rejection of an allograft or xenograft.

The present application relates to a bi-functional therapeutic for treating cancer that includes a targeting component which targets a tumor-associated antigen and an enzyme which, when delivered to a tumor by said targeting component, converts the tumor phenotype to that of an incompatible allograft or xenograft. The enzyme is coupled to the targeting component. Also disclosed is a method for treating cancer comprising administering the bi-functional therapeutic.